{"id":10319,"date":"2021-06-10T10:32:15","date_gmt":"2021-06-10T17:32:15","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=10319"},"modified":"2021-06-11T10:33:09","modified_gmt":"2021-06-11T17:33:09","slug":"second-generation-antibodies-neutralize-emerging-sars-cov-2-variants-of-concern","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/06\/10\/second-generation-antibodies-neutralize-emerging-sars-cov-2-variants-of-concern\/","title":{"rendered":"Second Generation Antibodies Neutralize Emerging SARS-CoV-2 Variants of Concern"},"content":{"rendered":"<ul>\n<li style=\"font-weight: 400\"><i><span style=\"font-weight: 400\">[Pre-print, not peer-reviewed]<\/span><\/i><span style=\"font-weight: 400\"> AX290 and AX677 (AXON Neuroscience), second generation monoclonal antibodies developed specifically to target SARS-CoV-2 variants of concern, were experimentally shown to successfully neutralize the wild-type strain, B.1.1.7 (Alpha), and B.1.351 (Beta) in mouse models.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Kovacech et al.\u00a0(June 9, 2021). Second Generation Antibodies Neutralize Emerging SARS-CoV-2 Variants of Concern. Pre-print downloaded Jun 10 from <\/span><\/i><a href=\"https:\/\/doi.org\/10.1101\/2021.06.09.447527\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1101\/2021.06.09.447527<\/span><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>[Pre-print, not peer-reviewed] AX290 and AX677 (AXON Neuroscience), second generation monoclonal antibodies developed specifically to target SARS-CoV-2 variants of concern, were experimentally shown to successfully neutralize the wild-type strain, B.1.1.7 (Alpha), and B.1.351 (Beta) in mouse models. Kovacech et al.\u00a0(June 9, 2021). Second Generation Antibodies Neutralize Emerging SARS-CoV-2 Variants of Concern. Pre-print downloaded Jun 10&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/06\/10\/second-generation-antibodies-neutralize-emerging-sars-cov-2-variants-of-concern\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[67,32,159],"topic":[31],"class_list":["post-10319","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-antibodies","tag-immunity","tag-variants","topic-vaccines-and-immunity"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/10319","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=10319"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/10319\/revisions"}],"predecessor-version":[{"id":10320,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/10319\/revisions\/10320"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=10319"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=10319"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=10319"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=10319"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}